Cutaneous Langerhans Cell Histiocytosis Presenting in Adulthood

Histiocitosis de células de Langerhans cutánea de presentación en el adulto

To the Editor:

Langerhans cell histiocytosis (LCH) is a disease of clonal proliferation of immature Langerhans cells.1,2 LCH can affect any organ,3 occurs mainly in children, and is rare in adults. It is even rarer for it to be confined to the skin. We present 3 cases of adult-onset cutaneous LCH treated by surgical excision. No new lesions or systemic or other effects developed during follow-up.

Case 1: A 36-year-old man with no relevant medical history presented with an asymptomatic lesion that had appeared 2 months earlier. It was located on the external edge of the right eyebrow, and there were no associated symptoms. Physical examination showed it to be a papule 6 mm in diameter that was slightly erythematous, firm to the touch, and well defined (Fig. 1A). No other skin or mucosal lesions, palpable lymph nodes, or enlarged organs were detected. Histopathology of the excised tissue revealed a normal epidermis and a dense, nodular-type infiltrate (Fig. 2A) composed of dispersed cells with oval or kidney-shaped nuclei resembling coffee beans (Fig. 2B). The cells had a clear eosinophilic cytoplasm, corresponding to histiocytes. The infiltrate also contained necrotic areas, lymphocytes, and eosinophils. The mitotic index was very low. Immunohistochemical staining was positive for S100, CD1a (Fig. 2C and 2D) and CD207 (langerin) and negative for CD68. With these findings we made the diagnosis of LCH and ordered the following additional tests and imaging studies: complete blood count, coagulation screen, biochemistry, hormone profile, urine analysis, chest radiograph, abdominal ultrasound, and bone scans. All findings were normal. The final diagnosis was adult-onset LCH confined to the skin.

The patient has remained asymptomatic for 3 years. No new skin lesions, systemic symptoms, or related disorders have developed.

Case 2: A 33-year-old woman reported that an asymptomatic lesion had appeared on her left forearm 6 months earlier. It was an erythematous, infiltrated papule 5 mm in diameter (Fig. 1B). No enlarged lymph nodes or organs were found on physical examination. The lesion was removed, and the histopathologic findings, similar to those described in the first case, were consistent with a diagnosis of LCH. The results of additional tests were negative, and no new lesions or other clinical or analytic abnormalities have appeared in 2 years of follow-up.

Case 3: A 49-year-old woman presented with 2 erythematous, papular lesions 5 and 7 mm in diameter located on her right cheek and back. She also had a 9-mm plaque on the left side of her neck (Fig. 1C). No abnormalities were found on physical examination. Histopathology of an excised lesion was consistent with LCH, and so the remaining two were also removed. The histologic findings were the same. Additional studies gave no positive results. No new lesions or new conditions have developed in 3 years of follow-up.

LCH is a rare disease that is diagnosed mainly in children under the age of 15 years. Over that age, the estimated incidence is 5 to 9 cases per million population.1,4 The spectrum of clinical presentations ranges widely,2,3 varying according to the organ affected. In some cases lesions are solitary and resolve on their own, whereas in others the disease is disseminated and life-threatening.3,4,6,10 The recent classification system of the Histiocyte Society refers specifically to a Langerhans (L) group of diseases.3 Diagnosis is based on clinical, radiologic, and histopathologic findings, the last of which identifies a histiocytic infiltrate with the characteristic immunophenotypic features of LCH. The disease can affect any organ but is mainly found in bones, skin, hypophysis, liver, spleen, lymph glands, and lungs; less often, the central nervous (other than at the hypophysis) and hematopoietic systems are involved.3,4

The pathogenesis of LCH remains unclear.3,4,6,7 The BRAF V600E mutation, which overstimulates the MAPK pathway, is present in half of patients with LCH. Smaller proportions of patients carry the MAP2K1 MEK1 or MAP3K1 ARF mutations. Mutations in the PICK1 and PICK3R2 genes, affecting the PIK3CA pathway, have also been described.4 These findings support the theory that LCH is a neoplastic process.3,4 However, the inflammatory component and the
fact that the clinical course is sometimes benign suggest a
reactive process. Cases of familial LCH have been reported,
though no genetic predisposition has yet been identified.4

Adult-onset LCH confined to the skin is very rare.1,5,8 This
form may present as a solitary papular or nodular lesion,
with or without ulceration, or as multiple lesions.1,9 It may
even mimic other skin diseases.10 In a series of 18 patients
who presented with cutaneous lesions, the ages ranged from
20 to 89 years and no pattern related to race or gender was
identified.1 Nearly half (8/18) had solitary lesions (papules
or nodules) or ulcerated lesions in skin folds. On further
study, bone involvement was found in 1 of these patients
and myelodysplastic syndrome was diagnosed in 2 of them.
During a mean follow-up period of 41 months, 2 patients
developed noncutaneous LCH and 5 patients were diagnosed
with progressing blood tumors (2 cases of myelomonocytic
leukemia and 1 case each of histiocytic sarcoma, diffuse
large B-cell lymphoma, and peripheral T-cell lymphoma). The
authors of that series also reviewed the literature, finding 74 patients with initial presentations involving the
skin, 4 of whom had extended histiocytosis and 8 of whom
had blood diseases found during diagnosis or follow-up. The
authors suggested that the association between LCH and
myelomonocytic disorders could be related to the common
origin of the cells in bone marrow.1 LCH is currently thought
to arise in myeloid dendritic cells of the bone marrow,
which express the same antigens as cutaneous Langerhans
cells.

The differential diagnosis of LCH includes several neo-
plastic and inflammatory diseases.10 Knowledge of the
diseases’ immunophenotype is therefore essential for a
firm diagnosis. Histology must demonstrate an infiltrate
of Langerhans cells positive for CD1a and/or CD207
(langerin),3,6 a criterion that has replaced the finding of Bir-
beck granules by electron microscopy.6 Positive staining for
CD207 rules out indeterminate cell histiocytosis.4

Searching for possible extension of disease to other tis-
sues and follow-up are essential when treating adults
with skin lesions to rule out LCH in other locations and concur-
rent conditions.1,6 Findings will be mainly blood disorders,
such as typically occur in children. Tests and imaging
studies recommended for adults with LCH include a complete
blood count, biochemistry, chest radiograph, hormone pro-
file, bone scans, and abdominal ultrasound; these studies

Figure 1 A, Slightly erythematous papular lesion at the edge of the right eyebrow. B, Erythematous lesion on the left forearm. C, Slightly erythematous plaque on the left side of the neck.

Figure 2 A, Dense, nodular-type infiltrate in the dermis, with areas of necrosis; hematoxylin-eosin, magnification ×10. B, Histiocytes with oval or kidney-shaped nuclei resembling coffee beans and clear cytoplasm; accompanied by lymphocytes and eosinophils (hematoxylin-eosin, magnification ×20). C and D, Immunohistochemical staining was positive for S100 and CD1a, respectively.
are ordered at baseline and every 6 months during follow-up for asymptomatic patients. A full physical examination, complete blood count and biochemistry, and abdominal ultrasound as well as a chest radiograph are usually ordered annually for at least 3 years. Bone marrow should be biopsied if infiltration is suspected, although some authors believe the procedure should be routine.

Because LCH in the adult is so rare, optimum treatment has not been established. The prognosis is good for patients with LCH confined to a single organ or system, but they should be followed closely. Local treatments (surgery, topical corticosteroids, or corticosteroid infiltrations) can be used. Multiple, ulcerated, or resistant lesions can be treated with systemic corticosteroids, phototherapy, radiotherapy, interferon, and various chemotherapeutic regimens. It has been suggested that ulceration may affect the prognosis, although to date the reported outcomes have been inconsistent.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

Drs Juan Luis Santiago Sánchez-Mateos and Claudia Ramos-Rodriguez collaborated in preparing this report.

References


M.A. Flores-Terry, a,b J.L. Sanz-Trenado, b M. García-Arpa, a M.P. Cortina-de la Calle a Servicio de Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
b Servicio de Anatomía Patológica, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

Corresponding author.
E-mail address: miguelterry85@hotmail.com

(M.A. Flores-Terry).

1 August 2017 26 December 2017

To the Editor:

Nail psoriasis is a common complaint in psoriasis. It can be a sign of severe disease and must be taken into account when choosing a treatment aimed at reducing pain, functional disability, and emotional stress. An estimated 90% or so of patients with psoriasis will develop nail psoriasis at some stage in their lifetime, although the condition is uncommon in the pediatric population (prevalence, 7%-13%).

Nail psoriasis can have a major impact on patient quality of life, as it can cause intense pain or interfere with the ability to pick up small objects or perform fine motor movements. We present our experience with 8 patients (4 men and 4 women) with a mean (SD) age of 59.8 (8) years with psoriatic arthritis (PsA) and severe nail damage treated with certolizumab pegol (CZP) monotherapy using the standard dosage of 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks. CZP is a TNF inhibitor formed

Nail Psoriasis Treated With Certolizumab Pegol in Patients With Psoriatic Arthritis: Preliminary Observation

Psoriasis ungual tratada con certolizumab pegol en pacientes con artritis psoriásica: conclusión preliminar

© 2018 Elsevier España, S.L.U. and AEDV. Published by Elsevier España, S.L.U. All rights reserved.

To cite this article as: Mazzeo M, Dattola A, Cannizzaro MV, Bianchi L. Psoriasis ungual tratada con certolizumab pegol en pacientes con artritis psoriásica: conclusión preliminar. Actas Dermosifiliogr. 2019;110:169-171.